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Abstract
Background: Vesicular stomatitis virus (VSV) is the prototypic rhabdovirus and the best studied
member of the order Mononegavirales. There is now compelling evidence that enveloped virions
released from infected cells carry numerous host (cellular) proteins some of which may play an
important role in viral replication. Although several cellular proteins have been previously shown
to be incorporated into VSV virions, no systematic study has been done to reveal the host protein
composition for virions of VSV or any other member of Mononegavirales.
Results: Here we used a proteomics approach to identify cellular proteins within purified VSV
virions, thereby creating a "snapshot" of one stage of virus/host interaction that can guide future
experiments aimed at understanding molecular mechanisms of virus-cell interactions. Highly
purified preparations of VSV virions from three different cell lines of human, mouse and hamster
origin were analyzed for the presence of cellular proteins using mass spectrometry. We have
successfully confirmed the presence of several previously-identified cellular proteins within VSV
virions and identified a number of additional proteins likely to also be present within the virions. In
total, sixty-four cellular proteins were identified, of which nine were found in multiple preparations.
A combination of immunoblotting and proteinase K protection assay was used to verify the
presence of several of these proteins (integrin 1, heat shock protein 90 kDa, heat shock cognate
71 kDa protein, annexin 2, elongation factor 1a) within the virions.
Conclusion: This is, to our knowledge, the first systematic study of the host protein composition
for virions of VSV or any other member of the order Mononegavirales. Future experiments are
needed to determine which of the identified proteins have an interaction with VSV and whether
these interactions are beneficial, neutral or antiviral with respect to VSV replication. Identification
of host proteins-virus interactions beneficial for virus would be particularly exciting as they can
provide new ways to combat viral infections via control of host components.
Background
The order Mononegavirales contains four families (Rhab-
doviridae, Paramyxoviridae, Filoviridae and  Bornaviridae),
which include many lethal human pathogens (e.g. rabies,
Ebola, and Hendra viruses); highly prevalent human
pathogens, such as the respiratory syncytial and parainflu-
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enza viruses; potential ethological agents of some neu-
robehavioral abnormalities and psychiatric disorders in
humans (Borna disease virus); as well as viruses with a
major economic impact on the poultry and cattle indus-
tries (e.g. Newcastle disease virus and rinderpest virus). All
members of this order share a similar genome organiza-
tion and common mechanisms of genome replication
and gene expression, and, as with other RNA viruses with
limited coding capacity, they exploit cellular proteins and
pathways to facilitate many aspects of their replication
cycle [1-3]. Identification of host-virus interactions can
provide new insights into viral biology and developing
new ways to combat viral infections via control of host
components.
Vesicular stomatitis virus (VSV) is the best studied mem-
ber of Mononegavirales  and the prototypic rhabdovirus.
There is now compelling evidence that enveloped virions
(including members of Mononegavirales) released from
infected cells carry numerous host (cellular) proteins
some of which may play an important role in viral repli-
cation [4]. Several cellular proteins have been previously
shown to be incorporated into VSV virions including
tubulin [5], cyclophilin A [6], translation elongation fac-
tor 1 alpha (EF1a) [7], RNA guanylyltransferase [8], casein
kinase II [9] and heat shock cognate 71 kDa protein
(Hsc70, also known as HSPA8) [10]. However, to the best
of our knowledge, no systematic study has been done to
reveal the host protein composition for virions of VSV or
any other member of Mononegavirales.
A proteomics approach utilizing mass spectrometry (MS)
has been used to successfully identify cellular proteins in
a number of enveloped viruses including poxviruses [11-
13], herpesviruses [14-20], orthomyxoviruses [21], coro-
naviruses [22], and retroviruses [23-25]. Here we
attempted the same strategy to identify cellular proteins
within purified VSV virions, thereby creating a "snapshot"
of one stage of virus/host interaction that can guide future
experiments aimed at understanding molecular mecha-
nisms of virus-cell interactions. Using this approach, we
confirmed the presence of several previously-identified
cellular proteins within VSV virions and identified a
number of additional proteins.
Results
Purification of VSV from different cell types
Several cell lines [including BHK21 (hamster), HeLa
(human), A549 (human), HEp2 (human), MIA PaCa
(human), 4T1 (mouse), 3T3 (mouse), 3T10 (mouse), 2H-
11 (mouse), MOVAS (mouse) and Vero (green monkey)]
were tested for their ability to support robust replication
of VSV and produce high titers of virus, which is required
for successful purification and subsequent proteomic
analysis. Based on this analysis (data not shown), we
selected three cell lines, capable of producing the high
VSV titers: BHK21 (baby hamster kidney cells), 4T1
(mouse mammary tumor cells) and A549 (human lung
carcinoma cells) (Fig. 1). BHK21 has been extensively
used as a standard cell line for growing VSV. A549 and 4T1
cells also supported suitable viral replication although to
lower titers than BHK21 cells (Fig. 2B). The use of differ-
ent cell lines allowed us to compare viral host protein con-
tent across species and cell types. In addition, the A549
and 4T1 cell lines were included to allow identification of
cellular proteins potentially lacking sufficient homology
to human or mouse proteins to be recognized from a
hamster source (BHK21).
To grow and purify viruses, BHK21 cells were infected
with VSV HR1 (Indiana serotype), while A549 and 4T1
cells were infected with VSV wild type (VSV-wt, Indiana
serotype). VSV HR1 is a well characterized mRNA cap
methylation defective VSV (Indiana serotype) host-range
(hr) mutant which has a delay in replication but achieves
wild type titers in BHK21 [26-29]. VSV HR1 was chosen
for BHK21 infection as the milder cytopathic effect in
BHK21 cells compared to VSV-wt aid exclusion of cellular
debris (data not shown). However, VSV-wt was used for
Overview of the experimental procedure used in this study Figure 1
Overview of the experimental procedure used in this 
study.
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infection of A549 and 4T1 cells as replication of VSV HR1
was more inhibited in these two cell lines than in BHK21
due to its host-range growth phenotype (data not shown)
and the cytopathic effect caused by VSV-wt in these cells
was not as rapid or severe as seen with BHK21.
Virus containing media was collected at 20-28 hours (h)
post infection (p.i.) when most cells were infected but sig-
nificant cell detachment had not yet occurred (to maxi-
mize exclusion of cellular debris), and virions were
purified using a discontinuous sucrose gradient purifica-
tion protocol as described in the Materials and methods
section. Initial concentration of virus by polyethylene gly-
col precipitation [30] as well as the use of continuous
sucrose [30], cesium chloride [31], and iodixanol gradi-
ents [32] were also tried without significant improvement
in sample infectivity or purity (data not shown).
Virion samples were examined by transmission electron
microscopy (EM) for the presence of nonviral structures
and to assess virion integrity. As shown in Figure 2A, the
sample derived from BHK21 cells was primarily com-
posed of particles readily recognizable as VSV although
the possibility of some cellular contaminants cannot be
ruled out. In addition to standard "bullet shaped" parti-
cles, there were also large numbers of "bent" particles
where the virion appears to have been broken in half.
These bent particles have been shown to be a substantial
component of at least some VSV preparations and are
infectious [31]. The presence of other "irregular" particles
is consistent with previous studies demonstrating that
VSV virions can easily undergo morphological changes
Figure 2
Characterization of purified VSV virion preparations Figure 2
Characterization of purified VSV virion preparations. 
(A) Electron micrographs of the purified virion preparations 
from BHK21 (two different fields are shown), 4T1 and A549. 
Virions were absorbed to carbon-formvar coated grids and 
negatively stained with 2% uranyl acetate. (B) Infectivity 
(PFU/ml) of purified virions shown in (A) was calculated by 
standard plaque assay on BHK21 cells. Total protein concen-
tration of these preparations was determined using a Brad-
ford assay, and infectivity per total protein (PFU/g) was 
calculated based on these two values. (C) Total RNA was 
extracted from uninfected (mock) or infected BHK21 cells 
or from purified virion samples containing 25 g of protein, 
and analyzed by Northern blotting. RNA was separated on a 
1.5% agarose-formaldehyde gel, transferred to a nylon mem-
brane and detected using a probe complimentary to the 3' 
end of VSV genome. (D) 50 g of total protein from each 
purified virion preparation was separated on a 10% SDS-
PAGE gel, and stained with Coomassie Brilliant Blue R250. 
Numbered boxes indicate the gel segments cut out and ana-
lyzed by mass spectrometry.Virology Journal 2009, 6:166 http://www.virologyj.com/content/6/1/166
Page 4 of 16
(page number not for citation purposes)
when processed for visualization by EM [33,34]. In con-
trast to the BHK21 preparation, the virion preparations
from A549 and 4T-1 showed fewer intact virus particles,
and a large number of unwound nucleocapids could be
seen (Fig. 2A). Some of the membranous structures
present may represent the viral membranes dissociated
from the nucleocapsids, although the possibility of them
being cellular vesicles cannot be ruled out [35]. Consist-
ent with the differences observed by EM (Fig. 2A) was the
variation in the number of infectious particles per g of
total protein (Fig. 2B). However, when equal quantities of
total protein were separated on a 10% SDS-PAGE gel and
visualized by Coomassie staining (Fig. 2D) or analyzed by
immunoblotting against VSV proteins (data not shown),
the quantity and distribution of the viral proteins was
similar in all samples as were the intensity and number of
minor bands representing cellular or degraded viral pro-
teins. Additionally, when total RNA extracted from sam-
ples containing equal quantities of protein was analyzed
by Northern blotting using a probe complimentary to the
3' end of VSV genome, greater numbers of viral genomes
were recovered from purified virus samples from 4T1 and
A549 than from BHK21 cells (Fig. 2C). Smaller products
representing defecting interfering genomic RNAs were not
detected in any sample, even upon overexposure of the
membrane (data not shown). This supports our hypothe-
sis that the filament structures seen in Figure 2A for A549
and 4T1 virion preparations are unwound VSV nucleocap-
ids containing viral genomic RNA. That these filaments
are not cellular nucleic acids is also supported by the lack
of detection of any histone or ribosomal proteins in the
A549 and 4T1 samples by MS (Table 1). Together, the
Northern blot (Fig. 2C) and Coomassie staining (Fig. 2D)
data suggest the observed visual differences between sam-
ples (Fig. 2A) are at least in part due to differences in par-
ticle stability/infectivity rather than simply sample purity.
Identification of virion associated proteins using proteomic 
approach
For MS analysis, 50 g of total protein was separated on a
1-D SDS-PAGE gel, stained with Coomassie Brilliant Blue
R250 and gel bands were cut out for analysis as indicated
in Figure 2D. Gel pieces were subjected to in-gel trypsin
digestion and the resulting peptides were extracted from
the gel matrix, separated using reverse-phase nano-liquid
chromatography, analyzed by tandem MS [36], and
searched against human and mouse databases (concate-
nated with a VSV protein database), as described in the
Materials and methods section. All five VSV proteins were
identified by this analysis, as well as 64 cellular proteins
(Table 1) plus keratins (not shown in Table 1). Of the 64
proteins, nine were identified in more than one sample.
Five proteins [tubulin alpha, annexin A2, EF1a, ubiquitin
and integrin 1] were identified in all three samples while
tubulin beta, cytoplasmic actin and translation elongation
factor 2 were identified only in the BHK21 and 4T1
derived virion preparations; and transferin receptor pro-
tein 1 was identified only in the 4T1 and A549 derived
preparations.
Confirmation of virion incorporation for several cellular 
proteins
Several proteins [integrin 1, heat shock protein 90 kDa
(Hsp90), Hsc70, annexin 2, EF1a] identified by MS were
picked for analysis by immunoblotting to confirm their
presence in the virion preparations. 50 g of purified viri-
ons and 10 g of cellular lysate prepared from mock
infected cells or cells infected with VSV-wt harvested at 18
h p.i. were separated on SDS-PAGE gels and analyzed by
immunoblotting (Fig. 3B), as described in the Materials
and methods section.
To determine whether these selected cellular proteins
were incorporated within virions, a portion of purified
virions from BHK21 and 4T1 cells were treated with pro-
teinase K (ProK). ProK treatment degrades any proteins
associated with the exterior surface of the virion as well as
the exposed portion(s) of any membrane proteins, while
the viral envelope excludes ProK from the interior of the
virion, thereby protecting proteins incorporated into the
virion [37,38]. A portion of the treated virions from 4T1
cells were additionally purified by centrifugation through
a 20% sucrose cushion. This process removed the protei-
nase and cleaved peptides and aided removal of any resid-
ual contaminating vesicles as proteinase treatment would
decrease the density of vesicles to a greater extent than the
virions [39]. Due to insufficient quantities of purified vir-
ions from the preparations analyzed by MS, we were una-
ble to conduct all treatments with preparations from all
three cell lines.
As seen in Figures 3A and 3B, ProK treatment resulted in
the almost complete removal of the viral glycoprotein
(G). However, residual quantities of G could be visualized
by immunoblotting with anti-VSV antibodies, indicating
the process was not 100% efficient (data not shown). In
contrast, substantial amounts of the viral matrix (M),
nucleocapsid (N), phosphoprotein (P) and large
polymerase (L) proteins were protected from ProK activity
by the viral membrane, although we estimate that about
50% of these proteins were lost from the BHK21 derived
virions during this process, about 70% from the 4T1
derived virions and about 90% from the ProK treated and
additionally purified 4T1 derived virions. This loss of pre-
sumably membrane-protected proteins was likely due to
physical disruption of the virion membrane, and the dif-
ferences in protein loss were consistent with the varying
degrees of virion disruption observed by EM (Fig. 2A).
Due to the high loss of protein from the 4T1 derived sam-
ple, we were unable to obtain sufficiently concentratedVirology Journal 2009, 6:166 http://www.virologyj.com/content/6/1/166
Page 5 of 16
(page number not for citation purposes)
Table 1: Cellular proteins identified in purified virion preparations following 1-D SDS-PAGE and LC-MS/MS
Gel pieces found in d 
(No. of spectra/No. unique peptides)
Protein name Taxonomy a Accession 
No. b
Mass (kDa) BHK 4T1 A549 Other viruses 
found in e
Tubulin alpha H IPI00180675 50.1 3(11/9) Influenza [21], 
HCMV [19], VV 
[11,13], HIV-1 [23], 
ASFV [58].
M IPI00110753 50.1 3(11/10) 9(2/2) 15(2/2)
Annexin A2 H IPI00455315 38.6 2(8/4) 8(4/3) 14(3/2) Influenza [21], 
HCMV [19,59], VV 
[11], KSHV [20], 
HIV-1[23], HSV-1 
[18], AlHV-1 [15].
M IPI00468203 38.5 2(12/7) 8(5/4) 14(2/2)
Elongation factor 1-
alpha
H IPI00014424 50.5 3 (9/3) 9(9/4) HIV-1 [23,24,60,61], 
VV [11,13], MCMV 
[17], HCMV [19], 
SARS-CoV [22].
M IPI00307837 50.3 3(9/3) 9(13/6) 15(3/2)
Ubiquitin H IPI00719280 25.8 2(6/3),3(4/3), 
4(3/2),5(3/2)
8(8/3),9(7/3), 
11(2/2)
14(3/2), 17(2/2) Influenza [21], HIV-
1 [23,24,62], SIV 
[62], MMLV [25,62], 
VV [11,45], AcNPV 
[44], ASFV [45].
M IPI00923013 26.6 2(5/2),3(4/3), 
4(3/2),5(3/2)
8(7/3),9(6/2), 
10(2/2), 11(2/2)
14(3/2), 15(3/
2), 17(2/2)
Integrin beta-1 H IPI00217561 91.7c 6(2/2) 12(3/2) 18(6/2) Influenza [21], HIV-
1 [23], MMLV [25].
M IPI00132474 88.2c 6(3/3) 12(4/3)
Tubulin, beta H IPI00011654 49.7 3(11/7) 9(3/3) Influenza [21], 
HCMV [19], EBV 
[16], VV [11,13], 
MMLV [25], ASFV 
[58].
M IPI00109061 49.9 3(9/6) 9(3/3)
Actin, cytoplasmic H IPI00021439 41.7 4(3/2) 8(3/3) Influenza [21], 
HCMV [19], EBV 
[16], VV [11,12,63], 
KSHV [20] MMLV 
[25], HIV-1 [23,39], 
MCMV [17], HSV-1 
[18], ASFV [58], 
AlHV-1 [15], SeV 
[48], MV [49], RV 
[50].
M IPI00110850 41.7 4(3/2) 8(3/3)Virology Journal 2009, 6:166 http://www.virologyj.com/content/6/1/166
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Elongation factor 2 M IPI00466069 95.2 5(2/2) 11(3/2) HIV-1 [23], KSHV 
[20], HCMV [19], 
SARS-CoV [22].
Transferrin 
receptor protein 1
H IPI00022462 84.9c 17(3/2) HSV-1 [18], VV 
[64].
M IPI00124700 85.7c 11(2/2)
Low-density 
lipoprotein 
receptor-related 
protein 1, 85 kDa 
and 515 kDa 
subunits
H IPI00020557 504.5 5
(7/5), 6 (33/27)
M IPI00119063 504.7 5(7/5), 6(38/29)
Hsp90 H IPI00784295 84.8 5(8/7) HIV-1[23], VV [11], 
EBV [16], KSHV 
[20], HCMV [19], 
SARS-CoV [22].
M IPI00330804 84.6 5(8/8)
Neural cell 
adhesion molecule 
1
H IPI00435020 93.3c 2(2/2), 6(7/6)
M IPI00122971 119.3c 6(6/5)
Heat shock 
cognate 71 kDa 
protein
H IPI00003865 70.9 5 (8/6) MMLV [25], HIV-1 
[23,65], VV [11], RV 
[10], NDV [10], 
Influenza [10].
M IPI00323357 70.9 5(3/3)
Chondroitin sulfate 
proteoglycan 4
H IPI00019157 250.5 6(3/3)
M IPI00128915 252.4 6(5/5)
Prostaglandin F2 
receptor negative 
regulator
H IPI00022048 98.5c 6(4/4) MMLV [25], HIV-1 
[23].
M IPI00125497 106.0c 6(4/4)
Enolase H IPI00216171 47.1 3(2/2) Influenza [21], 
HCMV [19], EBV 
[16], KSHV [20], 
HIV-1 [23], VV [12].
M IPI00462072 47.0 3(4/4)
Annexin A5 H IPI00329801 35.8 2(5/3) Influenza [21], 
HCMV [19], HIV-
1[23], HSV-1 [18], 
VV [63].
M IPI00317309 35.7 2(4/2)
Table 1: Cellular proteins identified in purified virion preparations following 1-D SDS-PAGE and LC-MS/MS (Continued)Virology Journal 2009, 6:166 http://www.virologyj.com/content/6/1/166
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Synaptic vesicle 
membrane protein 
VAT-1 homolog
H IPI00156689 41.9 3(4/3)
M IPI00126072 43.1 3(2/2)
Annexin A4 M IPI00353727 35.8 2(3/2) Influenza [21].
ATP synthase alpha 
chain, 
mitochondrial
H IPI00440493 59.7 3(2/2)
M IPI00130280 59.7 3(2/2)
ATP synthase beta 
chain, 
mitochondrial
M IPI00468481 56.3 3(2/2) HIV-1 [23], VV [63].
Casein kinase I H IPI00167096 39.1 2(2/2)
M IPI00330729 38.9 2(2/2)
CD44 antigen H IPI00297160 39.4c 5(3/2) HIV-1 [23].
M IPI00223769 40.2c 5(2/2)
Fascin M IPI00353563 54.3 3(2/2) VV [12].
Fibronectin M IPI00113539 272.5 12(2/2) HIV-1 [23].
Guanine 
nucleotide-binding 
protein G(o), alpha 
subunit 2
M IPI00115546 39.9 2(3/2)
Histone H3.2 M IPI00230730 15.2 1(2/2)
Histone H4 H IPI00453473 11.2 1(2/2) MMLV [25], HIV-1 
[23], AlHV-1 [15], 
SARS-CoV [22].
M IPI00329998 11.4 1(2/2)
Methyl-CpG-
binding domain 
protein 4
M IPI00321709 62.6 3(2/2)
Monocyte 
differentiation 
antigen CD14
M IPI00308990 39.2 3(3/2) HIV-1 [23].
Pyruvate kinase M IPI00407130 58.0 3(2/2) Influenza [21], 
KHSV [20], HIV-1 
[23], VV [12,13], 
AlHV-1 [15].
Integrin alpha-3 M IPI00126090 116.7c 12(7/5) HIV-1 [23].
Annexin A3 M IPI00132722 36.2 8(4/4)
Envelope protein M IPI00406960 73.6 7(6/4)
Table 1: Cellular proteins identified in purified virion preparations following 1-D SDS-PAGE and LC-MS/MS (Continued)Virology Journal 2009, 6:166 http://www.virologyj.com/content/6/1/166
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Basigin M IPI00113869 29.7 9(3/3) HIV-1 [23].
EH-domain-
containing protein 
1
H IPI00017184 60.6 9(3/3)
M IPI00126083 60.6 9(3/3)
Gag protein M IPI00224370 60.3 7(4/3)
Lymphocyte 
antigen 74
M IPI00115558 35.0 8(3/3)
Tumor 
susceptibility gene 
101 protein
H IPI00018434 43.9 9(3/3) HIV-1 [23].
M IPI00117944 44.1 9(3/3)
Acid 
sphingomyelinase-
like 
phosphodiesterase 
3b
M IPI00117534 51.6 9(2/2)
Dystrophin M IPI00474450 425.8 8(2/2)
Guanine 
nucleotide-binding 
protein G(I)/G(S)/
G(T) beta subunit
H IPI00003348 37.2 8(3/2)
M IPI00116938 37.2 8(3/2)
H-2 class I 
histocompatibility 
antigen, D-D alpha 
chain
M IPI00110805 41.1 9(2/2)
H-2 class I 
histocompatibility 
antigen, L-D alpha 
chain
M IPI00109996 40.7 9(2/2)
L-lactate 
dehydrogenase A 
chain
M IPI00319994 36.3 8(2/2) HCMV [19], VV 
[12], SARS-Cov 
[22].
Monocarboxylate 
transporter 1
M IPI00137194 53.3 8(2/2)
Myosin-9 H IPI00019502 226.4 12(2/2) VV [11], KHSV [20].
T-complex protein 
1 subunit beta
M IPI00320217 57.3 9(2/2) HIV-1 [23].
Transmembrane 
protease, serine 
11E
M IPI00222870 50.0 9(2/2)
Table 1: Cellular proteins identified in purified virion preparations following 1-D SDS-PAGE and LC-MS/MS (Continued)Virology Journal 2009, 6:166 http://www.virologyj.com/content/6/1/166
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Ubiquitin protein 
ligase E3 
component n-
recognin 4
M IPI00378681 572.3 8(2/2)
4F2 cell-surface 
antigen heavy chain
H IPI00027493 57.9c 17(9/7) HIV-1 [23].
Albumin H IPI00022434 71.7 14(3/3) HIV-1 [23].
Annexin A1 H IPI00218918 38.6 14(3/3) Influenza [21], 
HCMV [19], VV 
[11], HIV-1[23], 
MCMV [17], HSV-1 
[18], AlHV-1 [15].
CD109 antigen H IPI00152540 161.7 18(3/3)
Transmembrane 
protein 2
H IPI00170706 154.4 18(3/3)
Aminopeptidase N H IPI00221224 109.4 18(2/2) HIV-1 [23], HCMV 
[19].
Integrin alpha-V M IPI00319509 109.5 18(2/2) HIV-1 [23].
H IPI00027505 116.0 18(2/2)
Lutheran blood 
group glycoprotein
H IPI00002406 67.4c 17(2/2)
Neutral amino acid 
transporter B(0)
H IPI00019472 56.6c 17(2/2)
Programmed cell 
death 6 interacting 
protein
H IPI00246058 96.8 17(2/2) MMLV [25], HIV-1 
[23].
Ras-related protein 
Rab-11B
M IPI00135869 24.3 13(2/2)
Ras-related protein 
Rap-1A
M IPI00138406 21.0 13(2/2) HIV-1 [23].
Solute carrier 
family 2, facilitated 
glucose transporter 
member 1
H IPI00220194 54.1c 17(2/2)
M IPI00308691 53.9c 17(2/2)
T-complex protein 
10a
M IPI00122340 47.1 18 (3/2)
a From search of human (H) or mouse (M) database
b International protein index accession numbers
c Glycosylated protein
d Gel bands were numbered as depicted in Figure 2D
e ASFV, African swine fever virus; AlHV-1, Alcelaphine herpesvirus-1; AcNPV, Autographa californica nuclear polyhedrosis virus; EBV, Epstein-Barr 
virus; HCMV, human cytomegalovirus; HIV-1, human immunodeficiency virus-1; KSHV, Kaposi's sarcoma-associated herpesvirus; MV, measles virus, 
MMLV, Moloney murine leukemia virus; MCMV, murine cytomegalovirus; NDV, Newcastle disease virus; RV, rabies virus; SeV, Sendai virus; SARS-
CoV, severe acute respiratory syndrome coronavirus; SIV, simian immunodeficiency virus; VV, vaccinia virus
Table 1: Cellular proteins identified in purified virion preparations following 1-D SDS-PAGE and LC-MS/MS (Continued)Virology Journal 2009, 6:166 http://www.virologyj.com/content/6/1/166
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ProK-treated virions derived from 4T-1 cells without addi-
tional purification, so slightly less than 50 g of this virus
was used for immunoblotting (Fig. 3A-B, sample 4T-1 +
ProK).
The presence of integrin 1, Hsp90, Hsc70, annexin 2 and
EF1a in the virion preparations was confirmed by immu-
noblotting. With the exception of integrin 1, all of the
proteins could be detected in at least one of the ProK
treated samples at levels similar to the untreated samples.
The reason for the variable responses of the ProK treated
samples is not known, however, the presence of a protein
in the ProK treated and additionally purified VSV
("4T1+ProK+Purify" sample, Fig. 3A-B) would strongly
indicate the presence of the protein within virions. This
sample consistently showed a high level of protection of
these proteins except for annexin 2 which can be located
either intracellularly or on the extracellular membrane,
and therefore a portion of it is likely vulnerable to ProK
degradation [40]. In contrast, for integrin 1, where the
extracellular domain is expected to be outside of the viral
membrane, the protein levels were greatly reduced in all
proteinase K treated samples, as seen for the viral G pro-
tein. Figure 3
B.
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Verification of protein incorporation within the virion prepa- rations Figure 3
Verification of protein incorporation within the vir-
ion preparations. Purified virion preparations (shown in 
Figure 2A) were left untreated (-ProK) or were treated with 
Proteinase K (+ProK) for 1.5 h at 37°C to remove all surface 
exposed proteins. Following ProK treatment, one 4T1-
derived virion sample was also centrifuged through a 20% 
sucrose gradient to remove ProK and free floating peptides 
(+ProK +Purify). (A) 5 g of total protein from untreated 
purified virions or the viral protein equivalent from the ProK 
treated samples were separated on a 10% SDS-PAGE gel and 
stained with Coomassie Brilliant Blue R250. Asterisk indi-
cates position of the ProK protein above the M protein. G 
degr., indicates VSV G protein fragment(s) generated as a 
result of ProK treatment. (B-D) Immunoblots were per-
formed using 10 g cellular lysate from mock infected or 
VSV-wt (+VSV) infected cells harvested at 18 h p.i. or 10 g 
of heat shocked (+heat) cellular lysates harvested after a 4 h 
incubation at 43°C, and 50 g of total protein from ProK 
treated or untreated purified virion preparations. Proteins 
were separated on gradient 8-16% (B and C) or 15% SDS-
PAGE (D) gels, transferred to PVDF membranes and rapidly 
stained with the reversible dye Ponceau S prior to the use of 
antibodies to confirm levels of viral proteins (cellular pro-
teins were not detectable). Primary antibodies were against 
integrin 1, heat shock protein 90 kDa (Hsp90), translation 
elongation factor 1 alpha (EF1), annexin 2, heat shock cog-
nate 70 kDa (Hsc70), stress-inducible 70 kDa heat shock 
protein (Hsp72), and cyclophilin A, as indicated.Virology Journal 2009, 6:166 http://www.virologyj.com/content/6/1/166
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We also analyzed untreated virion samples for two pro-
teins not detected by our MS analysis. The stress-inducible
70 kDa heat shock protein 70 (Hsp72, also known as
Hsp70 and HSPA1A), previously shown to enhance mea-
sles virus transcription [41,42] and determine measles
neurovirulence in mice [43], was readily detectable by
immunoblotting in lysates prepared from cells heat
shocked at 43°C for 4 h (Fig. 3C). Without heat shock,
Hsp72 was also easily detected in A549 lysates, weakly
detected in 4T-1 lysates and not detected at all in BHK21
lysates. In keeping with this, Hsp72 could be detected in
virions from A549 cells but was not seen in virions from
4T1 or BHK21 cells. That Hsp72 was detected equally well
in all the heat shocked lysates suggests these differences
are not solely due to variable antibody recognition of
Hsp72 from different sources. VSV infection did not
appear to induce Hsp72 expression at the time point ana-
lyzed. Immunoblotting also confirmed the presence of
cyclophilin A (Fig. 3D) in virions derived from BHK21
and 4T1 cells (the A549 preparation was not tested for this
protein).
Discussion
In this study, we conducted the first systematic study of
the cellular protein composition of VSV virions. To com-
pare host protein content of VSV virions across species
and cell types, we analyzed virions isolated from three dif-
ferent cell types of human, mouse and hamster origin. In
total, our analysis successfully identified all five VSV pro-
teins as well as 64 cellular proteins (Table 1), plus kerat-
ins. For the majority of the identified proteins, the
predicted molecular weight was consistent with the size
range encompassed by the 1-D SDS-PAGE gel slice the
protein was found in, which served as an additional con-
firmation of the cellular protein identity. However, the
two groups of proteins, keratins (identified but not shown
in Table 1) and ubiquitin (Table 1), were broadly distrib-
uted among the gel slices. Keratins are common environ-
mental contaminants and their broad distribution among
the gel slices without correlation to the predicted molecu-
lar weight suggests contamination as the primary source
of the keratin peptides identified in our MS analysis.
Ubiquitin was also detected across a wide range of molec-
ular weights, suggesting that at least some viral and/or cel-
lular proteins within VSV virions are ubiquitinated,
although phospholipid anchored ubiquitin (not linked to
any protein) has been found in the envelopes of several
different viruses [44,45]. Further studies are needed to
determine the functional role of ubiquitin association
with VSV virions.
Of the 64 identified proteins, relatively few were identi-
fied in multiple samples originated from different cell
sources. Five proteins [tubulin alpha, annexin A2, EF1a,
ubiquitin and integrin 1] were identified in all three
samples while tubulin beta, cytoplasmic actin and transla-
tion elongation factor 2 were identified only in the
BHK21 and 4T1 derived virion preparations; and trans-
ferin receptor protein 1 was identified only in the 4T1 and
A549 derived preparations. There are several possible
explanations for this limited overlap including: (1) Limi-
tations in the ability of MS to detect certain proteins, par-
ticularly those found in low abundance; (2) Differences in
sample quality between the three preparations; (3) Cell
specific differences in gene expression or virus assembly;
(4) Some proteins of hamster origin (BHK21) potentially
lack sufficient homology to be identified using the mouse
or human databases used in this study.
Consistent with the first possibility, Hsp90 and Hsc70
were detected by MS only in the BHK21 derived virions.
However, when examined by immunoblotting (Fig. 3B),
Hsp90 was detected in all three virion preparations, and
Hsc70 was detected in the BHK21 and 4T1 virion prepara-
tions (the antiserum did not react strongly with Hsc70
from A549, preventing any conclusion about this sam-
ple). Importantly, of the 64 proteins, 35 were identified
on the basis of only two unique peptides while for other
14 proteins only three unique peptides were identified.
All this suggests other proteins may also be present in
multiple virion preparations despite being detected in
only a single sample by MS.
In regard to the second possibility, the sample derived
from BHK21 cells was primarily composed of particles
readily recognizable as VSV, while the virion preparations
from A549 and 4T-1 cells showed fewer intact virus parti-
cles and a large number of unwound VSV nucleocapids
containing viral genomic RNA (Fig. 2A), and had a lower
infectivity per g of protein. Therefore, it is possible that
some of the cellular proteins normally present within viral
particles were "leaked out" during virus purification from
A549 and 4T1 cells (accounting for their absence in those
preparations). Furthermore, it is possible that some cellu-
lar proteins found in the A549 and 4T1 preparations are
associated with free nucleocapsids rather than the virions.
These differences in virion properties may have also
impacted some of the other assays used in this study. For
example, genome isolation may have been more efficient
from the A549 and 4T1 samples, perhaps partially
accounting for the higher number of genomes detected in
these preparations. It may have also had an effect on the
proteinase K assay as suggested by the fact that approxi-
mately 70% of the supposedly internal viral proteins were
degraded when virions isolated from 4T1 cells were
treated with proteinase K as opposed to approximately
50% for virions isolated from BHK21 cells.
The variability in proteins identified in the different virus
preparations could also be due to cell specific differencesVirology Journal 2009, 6:166 http://www.virologyj.com/content/6/1/166
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in gene expression or virus assembly. An apparent exam-
ple of the former is Hsp72 which has been shown to
enhance measles virus transcription [41,42] and is a deter-
minant of measles neurovirulence in mice [43]. This pro-
tein was not specifically detected by our MS analysis
although the closely related and constitutively expressed
Hsc70 protein was identified (Table 1 and Figure 3), as
were several peptides common to both Hsc70 and Hsp72.
Upon heat shock, Hsp72 could be detected by immunob-
lotting in lysates from all three cell types, but in the
absence of this stress, was easily detectable in A549
lysates, weakly detected in 4T1 lysates and not detected at
all in BHK21 lysates. In keeping with this expression pro-
file, Hsp72 could be detected only in virions from A549,
demonstrating that, at least in some cases, host cell pro-
tein expression may affect incorporation of cellular pro-
teins into virions.
Using a MS approach, this study confirmed the presence
of several cellular proteins within VSV virions (tubulin
[5], translation elongation factor 1 alpha [7], and Hsc70
[10]). However, we were unable to detect at least three
proteins previously shown to be associated with VSV viri-
ons (cyclophilin A [6], cellular RNA guanylyltransferase
[8], and casein kinase II [9]) as well as several proteins
shown to bind individual VSV proteins including the beta
and gamma subunits of elongation factor 1 [7] and heat
shock protein 60 (Hsp60) [46]. Failure of our analysis to
detect some of these proteins does not challenge their
potential role in VSV replication, as these proteins may be
present within the virions but were not detectable in our
MS analysis, or, in the case of the protein interactions
shown outside the virion, the described interactions may
be transient. When two of our virus preparations were
tested for the presence of cyclophilin A by immunoblot-
ting, it was detected (Fig. 3D), demonstrating the list of
proteins generated by our MS analysis is not entirely
inclusive.
Due to the nature of a MS proteomics approach, it will be
necessary to confirm the presence of the identified pro-
teins within the VSV virion and their role is viral replica-
tion, as incorporation within the virion does not
necessarily imply a functional significance. "Accidental"
incorporation of cellular proteins is particularly likely to
occur during virus budding as abundant cytosolic proteins
can be trapped by the newly forming viral envelope and
host proteins are not excluded from the membrane used
to form the envelope. We have initiated this process for
several proteins of potential interest whose presence in
the virion has not previously been shown (Hsp90, actin,
annexin 2, and integrin 1), by confirming their presence
in our virion preparations by immunoblotting, and, for
the non-membrane proteins, confirming their presence
within the virion by proteinase K protection assay (Fig. 3B
and data not shown).
Pharmacological inhibition of Hsp90 or its knockdown
by siRNA has been shown to inhibit replication of several
negative-strand RNA viruses including VSV but its pres-
ence within VSV virions was not previously investigated
[47]. Actin has previously been shown to be incorporated
into Sendai [48], measles [49] and rabies [50] virions but
was not detected in VSV virions [50]. Here, using MS, we
have shown actin to be present within VSV as well (Table
1). Annexins bind phospholipids in a calcium dependent
manner and are believed to help direct membrane-mem-
brane and membrane cytoskeleton interactions. In partic-
ular, annexin 2 has been proposed to facilitate HIV-1
assembly at cellular membranes [23]. Integrin 1 forms
heterodimers with various alpha integrins that function in
both cell adhesion and cell signaling. While proteins
found in multiple preparations may not be more impor-
tant than those found only a single sample, the presence
of annexin 2 and integrin 1 in all three samples as well
as in a number of other viruses (for example, integrin 1
has also been detected in influenza, HIV-1 and Moloney
murine leukemia virus), suggests that these two proteins
may be involved in widely used viral processes (see far
right column of Table 1 for complete listing and refer-
ences). In fact, many of the cellular proteins identified in
our study have been found in association with the virions
of different RNA and DNA viruses (Table 1) suggesting
that enveloped viruses may use similar cellular pathways
for their assembly and exit from the cell. Currently, a sim-
ilar study using a proteomics approach is being conducted
in our laboratory to identify cellular proteins in virions of
other members of the family Mononegavirales. Such com-
parative analysis will reveal how similar or different the
cellular content of virions are among different members
of this order.
Conclusion
In summary, this is, to our knowledge, the first systematic
study of the host protein composition for virions of VSV
(or any other member of the order Mononegavirales). We
have successfully used a proteomic approach to confirm
the presence of several cellular proteins within VSV virions
and to identify a number of additional proteins likely to
also be present within the virions, some of which may
play an important role in VSV replication and possibly be
involved in previously unconsidered pathways in the
virus life cycle. However, we recognize the potential of
proteins not associated with virions to persist in our prep-
arations despite purification and that these would also be
identified by a global proteomics approach. Additionally,
the inclusion of a protein within the virion does not nec-
essarily imply a functional significance. Therefore, future
experiments are needed to determine which of the identi-Virology Journal 2009, 6:166 http://www.virologyj.com/content/6/1/166
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fied proteins interact with VSV and whether these interac-
tions are beneficial, neutral or antiviral with respect to
VSV replication. Identification of host proteins-virus inter-
actions beneficial for virus would be particularly exciting
as they can provide new ways to combat viral infections
via control of host components.
Materials and methods
Cells and viruses
The following cell lines were used in this study: Syrian
golden hamster kidney fibroblast cells (BHK21; ATCC#
CCL-10), mouse mammary gland adenocarcinoma cells
(4T1; ATCC# CRL-2539), and human epithelial lung car-
cinoma cells (A549; ATCC# CCL-185). Monolayer cul-
tures of these cell lines were maintained in Minimum
Essential Medium (Eagle's MEM, Cellgro) or in Dul-
becco's modified Eagle's medium (DMEM, Cellgro) sup-
plemented with 9% fetal bovine serum (FBS, Gibco) in a
5% CO2 atmosphere at 37°C. Infectivity (PFU/ml) of
virus stocks was calculated by standard plaque assay on
BHK21 cells. To grow and purify viruses, cells were
infected with wt or mutant VSV and incubated at 34°C.
BHK21 cells were infected with VSV HR1 at a multiplicity
of infection (MOI) of 0.005, while A549 and 4T1 cells
were infected with VSV wild type (VSV-wt, Indiana sero-
type) at an MOI of 0.1 and 0.5, respectively. VSV HR1 is a
well characterized mRNA cap methylation defective VSV
(Indiana serotype) mutant [26,28,29] with a mutation in
the L protein with a D to V substitution at position 1671
[26,27]. This mutation completely eliminates viral mRNA
cap methylation at both the guanine-N7 and 2'-O-adeno-
sine positions [26,27] and results in subsequent non-
translatability of primary VSV transcripts in non-permis-
sive cell lines [51-53]. As a result, VSV HR1 displays a
host-range (hr) phenotype characterized by severely
restricted growth in most cell types but only slightly
delayed growth in a limited number of "permissive" cells
including BHK21 cell line where it achieves wild type tit-
ers.
Virus purification and protease treatment
Virus containing media was collected at 20-28 hours (h)
post infection (p.i.) when most cells were infected but sig-
nificant cell detachment had not yet occurred (to maxi-
mize exclusion of cellular debris). The media was
centrifuged at 3000 × g for 10 minutes (min) to remove
large cellular debris and then at 71,000 × g and 4°C for 1
h in a Beckman SW32 Ti rotor to pellet the viral particles.
The viral pellet was resuspended in ET buffer (1 mM Tris-
HCl pH 7.5, 1 mM EDTA) with 10% DMSO and centri-
fuged in a 7-60% discontinuous sucrose gradient com-
posed of steps of 2 ml of 60% (w/w) sucrose, 3 ml of 45%
sucrose, 4.5 ml of 25% sucrose and 1.5 ml of 7% sucrose.
Sucrose solutions were made in HEN buffer (10 mM
HEPES pH 7.4, 1 mM EDTA, 100 mM NaCl). Following
centrifugation overnight at 130,000 × g and 4°C using a
Beckman SW40 Ti rotor, the virus containing band was
removed from the gradient and diluted with ET buffer.
The virus was pelleted by centrifugation at 130,000 × g
and 4°C for 1 h using a Beckman SW40 Ti rotor and resus-
pended in ET/DMSO buffer. Viral titers were determined
by standard plaque assay on BHK21 cells.
For protease treatment, purified virions from BHK21 and
4T1 cells were treated with 0.08 g proteinase K (ProK)
per 1 g total protein. After 1.5 h incubation at 37°C, phe-
nylmethanesulphonylfluoride (PMSF) was added to a
final concentration of 5 mM and the samples were incu-
bated on ice for 15 min to stop proteinase activity. A por-
tion of the treated virions from 4T1 cells were also
centrifuged through a 2 ml 20% sucrose cushion at
173,000 × g and 4°C for 2.5 h using a Beckman SW40 Ti
rotor. The pelleted virus was resuspended in ET buffer.
Electron microscopy
Virions were absorbed to carbon-formvar coated grids
(Electron Microscopy Sciences) by floating grids on 4 l
drops of sample for 1 min. Grids were blotted dry and
stained with 2% uranyl acetate in water for 30 seconds.
Excess stain was removed and the grids allowed to air dry.
Samples were visualized using a Philips CM10 transmis-
sion electron microscope.
Protein identification following 1D-SDS-PAGE
50 g of total protein from each purified virion sample
was separated on a 10% SDS-PAGE gel, stained with
Coomassie Brilliant Blue R250 and gel bands were cut out
for analysis. Gel pieces were subjected to in-gel trypsin
digestion and the resulting peptides were extracted from
the gel matrix, separated using reverse-phase nano-liquid
chromatography and analyzed by tandem MS as described
previously [36]. Briefly, samples were separated by a 68
min linear gradient from 90% Solvent I (0.1% formic acid
in water)/Solvent II (0.1% formic acid in acetonitrile) to
50% Solvent I/II at a flow rate of 500 nl/min on reversed
phase chromatography using a trap/elute method with a
in-house C18 sample trap in line with a C18 analytical col-
umn. The spectra were searched using the SEQUEST algo-
rithm of the Bioworks software (ThermoFisher, San Jose,
CA; version SRF v. 3) against the IPI.HUMAN.v.3.18 and
IPI.MOUSE.v.3.18 databases concatenated with a VSV
protein database. A parent ion mass tolerance of 2.0 Da,
fragment ion mass tolerance of 1.0 Da, and a 16 Da differ-
ential modification for methionine oxidation were used
for search parameters. Protein identifications were
accepted when the peptide probability was greater than
95.0% [54], the protein probability was greater than
99.0%, and contained at least 2 identified peptides. Scaf-
fold software was used for data compiling of each group
and calculating spectral count [55-57].Virology Journal 2009, 6:166 http://www.virologyj.com/content/6/1/166
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Northern blot analysis
Total RNA was extracted from purified virion samples
containing 25 g of protein using the QIAamp viral RNA
extraction kit (Qiagen), ethanol precipitated and resus-
pended in 30 l of RNase-free water. Half of this material
was separated on a 1.5% agarose-formaldehyde gel and
transferred to a nylon membrane. Following blocking
with hybridization buffer (Ambion) at 45°C, the mem-
brane was incubated overnight at 45°C in hybridization
buffer containing 30 ng/ml of a 5'-biotinylated oligonu-
cleotide complimentary to the first 55 nucleotides of the
VSV genome (5'-biotin-
GATCCTTAAGACCCTCTTGTGGTTTTTATTTTTTATCT-
GGTTTTGTGGTCTTCGT-3'). Following blocking with
TBS with 0.1% Tween 20 and 1% non-fat milk powder at
room temperature for 30 min, the membrane was incu-
bated with a streptavidin-horseradish peroxidase-conju-
gate in that same buffer for 1 h. The Enhanced
Chemiluminescence Plus (ECL+) protein detection sys-
tem (GE Healthcare) was used for detection and the mem-
brane was exposed to BioMax Light film (Kodak).
Protein gel electrophoresis and immunoblot analysis
Cellular lysates were prepared by mock infecting 4T-1,
A549 and BHK cells or by infecting them with VSV-wt at
MOIs of 0.5, 0.1 and 0.05 respectively. Cells were har-
vested at 18 h p.i. and lysed in RIPA buffer (25 mM Tris-
HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% Sodium deox-
ycholate and 0.1% SDS). For heat shocked lysates, unin-
fected cells were incubated at 43°C for 4 h and
immediately harvested. Protein concentrations of cellular
lysates and purified virions were determined by Bradford
assay. 50 g of purified virions and 10 g of cellular
lysates were separated on gradient 8-16% or 15% SDS-
PAGE gels, transferred to PVDF membranes and rapidly
stained with the reversible dye Ponceau S prior to the use
of antibodies to confirm levels of viral proteins and the
quality of protein transfer from gel to membrane. Mem-
branes were blocked in TBS (0.5 M NaCl, 20 mM Tris pH
7.5) with 0.1% Tween 20 and 5% non-fat milk powder
and then probed with antibodies against integrin 1 (N-
20; Santa Cruz Biotechnology), Hsp90 (68; BD Bio-
science), EF1a (D-15; Santa Cruz Biotechnology), annexin
2 (H-50; Santa Cruz Biotechnology), Hsc70 (1B5; Assay
Designs), Hsp72 (C92F3A-5; Assay Designs), or cyclophi-
lin A (2175; Cell Signaling Technology). Detection was
with species specific horseradish peroxidase-conjugated
secondary antibodies using the Enhanced Chemilumines-
cence Plus (ECL+) protein detection system (GE Health-
care) and exposure to BioMax Light film (Kodak).
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